Genmab — Remuneration Information 2014

Dec 15, 2014

Company Announcement

Copenhagen, Denmark; December 15, 2014 – Genmab A/S (OMX: GEN) announced today
that at a board meeting the board decided to grant 44,350 restricted stock
units to members of the board of directors and management and 157,525 warrants
to management and employees of the company as well as the company’s
subsidiaries.

Each restricted stock unit provides the owner with a right and obligation to
receive one share in Genmab A/S of nominally DKK 1. The fair value of each
restricted stock unit is equal to the closing market price on the date of grant
of one Genmab A/S share, DKK 337.40.

The restricted stock units will vest on the first banking day of the month
following a period of three years from the date of grant. Furthermore, the
restricted stock units are subject to vesting conditions set out in the
restricted stock unit program adopted by the board of directors in accordance
with the general guidelines for incentive-based remuneration adopted by the
shareholders at the annual general meeting. Information concerning Genmab’s
general guidelines for incentive-based remuneration can be found on
www.genmab.com under Investors > Corporate governance > Charters and guidelines

The exercise price for each warrant is DKK 337.40. Each warrant entitles the
owner to subscribe one share of nominally DKK 1. On the basis of an exercise
price of DKK 337.40 and by application of the Black-Scholes formula, the
average value of each warrant can be calculated as DKK 126.78 based on an
interest rate of 0.1710% and the historical volatility of Genmab A/S shares
calculated at 46.78%.

The warrants vest in blocks of 25% one, two, three and four years after the
grant date, and all warrants expire at the seventh anniversary of the grant
date. The new warrants were granted pursuant to the warrant plan adopted by the
board on April 25, 2012. Information concerning Genmab’s warrant schemes can be
found on www.genmab.com under Investors > Stock information > Warrants.

About Genmab A/S
Genmab is a publicly traded, international biotechnology company specializing
in the creation and development of differentiated human antibody therapeutics
for the treatment of cancer. Founded in 1999, the company currently has one
marketed antibody, Arzerra® (ofatumumab) for the treatment of certain chronic
lymphocytic leukemia indications and daratumumab in late stage clinical
development for multiple myeloma. Additionally Genmab has a clinical pipeline
with both late and early stage programs, and an innovative pre-clinical
pipeline. Genmab's technology base consists of validated and proprietary next
generation antibody technologies - the DuoBody® platform for generation of
bispecific antibodies, and the HexaBody™ platform which creates effector
function enhanced antibodies. Genmab's deep antibody expertise is expected to
provide a stream of future product candidates. Partnering of selected
innovative product candidates and technologies is a key focus of Genmab’s
strategy and the company has alliances with top tier pharmaceutical and
biotechnology companies. For more information visit www.genmab.com

Contact:
Rachel Curtis Gravesen, Senior Vice President, Investor Relations &
Communications
T: +45 33 44 77 20; M: +45 25 12 62 60; E: r.gravesen@genmab.com

This Company Announcement contains forward looking statements. The words
“believe”, “expect”, “anticipate”, “intend” and “plan” and similar expressions
identify forward looking statements. Actual results or performance may differ
materially from any future results or performance expressed or implied by such
statements. The important factors that could cause our actual results or
performance to differ materially include, among others, risks associated with
pre-clinical and clinical development of products, uncertainties related to the
outcome and conduct of clinical trials including unforeseen safety issues,
uncertainties related to product manufacturing, the lack of market acceptance
of our products, our inability to manage growth, the competitive environment in
relation to our business area and markets, our inability to attract and retain
suitably qualified personnel, the unenforceability or lack of protection of our
patents and proprietary rights, our relationships with affiliated entities,
changes and developments in technology which may render our products obsolete,
and other factors. For a further discussion of these risks, please refer to the
risk management sections in Genmab’s most recent financial reports, which are
available on www.genmab.com. Genmab does not undertake any obligation to update
or revise forward looking statements in this Company Announcement nor to
confirm such statements in relation to actual results, unless required by law.

Genmab A/S and its subsidiaries own the following trademarks: Genmab®; the
Y-shaped Genmab logo®; Genmab in combination with the Y-shaped Genmab logo™;
the DuoBody logo™; the HexaBody logo™; HuMax®; HuMax-CD20®; DuoBody®; HexaBody™
and UniBody®. Arzerra® is a registered trademark of the GSK group of companies.

Company Announcement no. 60
CVR no. 2102 3884

Genmab A/S
Bredgade 34E
1260 Copenhagen K
Denmark